161 related articles for article (PubMed ID: 36652664)
1. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.
Lak NSM; van Zogchel LMJ; Zappeij-Kannegieter L; Javadi A; van Paemel R; Vandeputte C; De Preter K; De Wilde B; Chicard M; Iddir Y; Schleiermacher G; Ruhen O; Shipley J; Fiocco M; Merks JHM; van Noesel MM; van der Schoot CE; Tytgat GAM; Stutterheim J
JCO Precis Oncol; 2023 Jan; 7():e2200113. PubMed ID: 36652664
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
[TBL] [Abstract][Full Text] [Related]
3. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM; Voormanns TL; Zappeij-Kannegieter L; van Zogchel LMJ; Fiocco M; van Noesel MM; Merks JHM; van der Schoot CE; Tytgat GAM; Stutterheim J
Clin Cancer Res; 2021 Oct; 27(20):5576-5585. PubMed ID: 34285060
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free DNA in Pediatric Rhabdomyosarcoma: Potential and Challenges.
Tombolan L; Zin A; Bisogno G
Methods Mol Biol; 2019; 1909():165-175. PubMed ID: 30580430
[TBL] [Abstract][Full Text] [Related]
5. Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors.
van Zogchel LMJ; Lak NSM; Verhagen OJHM; Tissoudali A; Gussmalla Nuru M; Gelineau NU; Zappeij-Kannengieter L; Javadi A; Zijtregtop EAM; Merks JHM; van den Heuvel-Eibrink M; Schouten-van Meeteren AYN; Stutterheim J; van der Schoot CE; Tytgat GAM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34820594
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of circulating tumor cells and cell-free DNA in pediatric rhabdomyosarcoma.
Tombolan L; Rossi E; Binatti A; Zin A; Manicone M; Facchinetti A; Lucchetta S; Affinita MC; Bonvini P; Bortoluzzi S; Zamarchi R; Bisogno G
Mol Oncol; 2022 May; 16(10):2071-2085. PubMed ID: 35212153
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract][Full Text] [Related]
8. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
[TBL] [Abstract][Full Text] [Related]
9. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study.
Terwisscha van Scheltinga SEJ; Wijnen MHWA; Martelli H; Rogers T; Mandeville H; Gaze MN; McHugh K; Corradini N; Orbach D; Jenney M; Kelsey A; Chisholm J; Gallego S; Glosli H; Ferrari A; Zanetti I; De Salvo GL; Minard-Colin V; Bisogno G; van Noesel MM; Merks HHM
Cancer Med; 2020 Oct; 9(20):7580-7589. PubMed ID: 32869534
[TBL] [Abstract][Full Text] [Related]
10. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
11. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
[TBL] [Abstract][Full Text] [Related]
12. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Analysis of the
Zhang N; Liu Z; Li K; Xing X; Long C; Liu F; She B; Che N
J Oncol; 2023; 2023():5888844. PubMed ID: 36691467
[TBL] [Abstract][Full Text] [Related]
14. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
18. Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma.
Salvianti F; Orlando C; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Pinzani P
Front Mol Biosci; 2015; 2():76. PubMed ID: 26779490
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
20. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
Nakatsuka T; Nakagawa H; Hayata Y; Wake T; Yamada T; Nishibatake Kinoshita M; Nakagomi R; Sato M; Minami T; Uchino K; Enooku K; Kudo Y; Tanaka Y; Kishikawa T; Otsuka M; Tateishi R; Koike K
J Gastroenterol; 2021 May; 56(5):456-469. PubMed ID: 33712873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
